Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of Patients
The introduction of molecular targeted agents and immunotherapy has expanded the chance of potential cure. The enrichment of dMMR, HER2-positive, and CPS-high tumors among potentially cured cases highlights the urgent need to develop effective therapies for those lacking actionable biomarkers.
Authors
- Takahiro Kinoshita (ORCID: https://orcid.org/0000-0001-7365-8733)
- Takeo Fujita
- Kohei Shitara (ORCID: https://orcid.org/0000-0001-5196-3630)
- Ukyo Okazaki
- Keigo Chida (ORCID: https://orcid.org/0000-0002-8377-1884)
- Kyosuke Seguchi (ORCID: https://orcid.org/0000-0002-8646-3094)
- Naoya Sakamoto (ORCID: https://orcid.org/0000-0003-0061-059X)
- Yuki Matsubara (ORCID: https://orcid.org/0000-0003-4009-0015)
- Takuya Ogura (ORCID: https://orcid.org/0000-0002-0972-9952)
- Tadayoshi Hashimoto (ORCID: https://orcid.org/0000-0003-3759-1214)
- Daisuke Kotani (ORCID: https://orcid.org/0000-0002-4196-555X)
- Masahiro Yura (ORCID: https://orcid.org/0000-0001-7102-9212)
- Hideaki Bando (ORCID: https://orcid.org/0000-0001-5041-2765)
- Izuma Nakayama (ORCID: https://orcid.org/0000-0003-4987-1934)
- Akinori Kobayashi
- Yasutoshi Kuboki (ORCID: https://orcid.org/0000-0003-3675-953X)
- Saori Mishima (ORCID: https://orcid.org/0000-0002-5922-1487)
- Yu Miyashita (ORCID: https://orcid.org/0000-0001-8278-4088)
- Takashi Kojima (ORCID: https://orcid.org/0000-0002-2554-8334)
- Dai Okemoto
- Mitsumasa Yoshida (ORCID: https://orcid.org/0000-0001-9238-2437)
- Yoshimasa Shimizu
- Takumi Habu
- Kazumasa Yamamoto (ORCID: https://orcid.org/0009-0005-4085-0741)
- Kazuma Sato
- Shigeru Ushiyama (ORCID: https://orcid.org/0009-0004-5390-8175)
Institutions
- Mito Red Cross Hospital (JP)
- National Cancer Center Hospital East (JP)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1200/op-25-00705
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00